Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Neuropharmacology. 2017 Jun 30;125:80–86. doi: 10.1016/j.neuropharm.2017.06.032

Table 1.

The ABHD6 inhibitor KT182, the COX-2 inhibitor valdecoxib, and nicotine do not substitute for the MJN110 (2.5 mg/kg) discriminative stimulus. Values represent mean ± SEM. n = 6–8 mice/group.

Drug (mg/kg) % MJN110 Aperture Responses/min
Vehicle 4.2 ± 1.9 26.7 ± 5.2
KT182 (1) 1.5 ± 0.8 30.6 ± 5.3
KT182 (2) 2.3 ± 1.0 27.1 ± 6.0

Vehical 1.4 ± 1.0 19.4 ± 2.1
Valdecoxib (10) 0.6 ± 0.3 17.8 ± 1.6

Vehicle 0.4 ± 0.4 26.4 ± 5.7
Nicotine (1.5) 2.7 ± 1.4 22.7 ± 3.8
HHS Vulnerability Disclosure